We view IPCA as a structural growth story, with all business segments contributing to growth. We expect IPCA to report 30% EPS CAGR over FY14-16, led by international generics. We reiterate Buy, with a target price of INR 1,025 (16x FY16E EPS). IPCA is one of our preferred picks in the midcap healthcare space
READ MORE »Download The Best Broker Research Reports On The Best Stocks
